Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells

Biochemical Journal

Volumn 442, Issue 2, 2012, Pages 273-282

  Liu, Ziwen ^a,b   Yan, Ruilan ^a   Al Salman, Ahmed ^a,c   Shen, Yi ^a   Bu, Yiwen ^a   Ma, Jun ^a   Luo, Di Xian ^a,d   Huang, Chenfei ^a   Jiang, Yuyang ^e   Wilber, Andrew ^a   Mo, Yin Yuan ^a   Huang, Mei Chris ^f   Zhao, Yupei ^b   Cao, Deliang ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF BAGHDAD   (Iraq)

^d THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^e TSINGHUA UNIVERSITY   (China)

^f MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Activator protein 1 (AP 1); Aldo keto reductase 1B10 (AKR1B10); Epidermal growth factor (EGF); Hepatocellular carcinoma (HCC); Insulin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR; INSULIN; PROTEIN AKR1B10; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARCINOMA CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ALDEHYDE REDUCTASE; ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; EPIDERMAL GROWTH FACTOR; FEMALE; GENES, FOS; HEP G2 CELLS; HUMANS; INSULIN; LIVER NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

MUS MUSCULUS;

EID: 84863136847     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20111322     Document Type: Article

References (48)

1. Cao, D., Fan, S. T. and Chung, S. S. (1998) Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273, 11429-11435 (Pubitemid 28272034)
2. Fukumoto, S., Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S. et al. (2005) Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785 (Pubitemid 40471839)
3. Yan, R., Zu, X., Ma, J., Liu, Z., Adeyanju, M. and Cao, D. (2007) Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 121, 2301-2306 (Pubitemid 47585613)
4. Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D. F. and Cao, D. (2009) Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 284, 26742-26748
5. Luo, D. X., Huang, M. C., Ma, J., Gao, Z., Liao, D. F. and Cao, D. (2011) Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway. Biochem. J. 438, 71-80
6. Shen, Y., Zhong, L., Markwell, S. and Cao, D. (2010) Thiol-disulfide exchanges modulate aldo-keto reductase family 1 member B10 activity and sensitivity to inhibitors. Biochimie 92, 530-537
7. Hyndman, D., Bauman, D. R., Heredia, V. V. and Penning, T. M. (2003) The aldo-keto reductase superfamily homepage. Chem. Biol. Interact. 143/144, 621-631 (Pubitemid 36246464)
8. Lee, K. W., Ko, B. C., Jiang, Z., Cao, D. and Chung, S. S. (2001) Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 12, 129-132
9. Barski, O. A., Tipparaju, S. M. and Bhatnagar, A. (2008) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab. Rev. 40, 553-624
10. Jin, Y. and Penning, T. M. (2007) Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 47, 263-292
11. Shen, Y., Zhong, L., Johnson, S. and Cao, D. (2011) Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem. Biol. Interact. 191, 192-198
12. Spite, M., Baba, S. P., Ahmed, Y., Barski, O. A., Nijhawan, K., Petrash, J. M., Bhatnagar, A. and Srivastava, S. (2007) Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem. J. 405, 95-105 (Pubitemid 46999929)
13. Martin, H. J. and Maser, E. (2009) Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem. Biol. Interact. 178, 145-150
14. Zhong, L., Liu, Z., Yan, R., Johnson, S., Zhao, Y., Fang, X. and Cao, D. (2009) Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha;, β-unsaturated carbonyls at physiological levels. Biochem. Biophys. Res. Commun. 387, 245-250
15. Zu, X., Yan, R., Robbins, S., Krishack, P. A., Liao, D. F. and Cao, D. (2007) Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol. Sci. 97, 562-568 (Pubitemid 47073870)
16. Balendiran, G. K. (2009) Fibrates in the chemical action of daunorubicin. Curr. Cancer Drug Targ. 9, 366-369
17. Zhong, L., Shen, H., Huang, C., Jing, H. and Cao, D. (2011) AKR1B10 Induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47
18. Ma, J., Yan, R., Zu, X., Cheng, J. M., Rao, K., Liao, D. F. and Cao, D. (2008) Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-α in breast cancer cells. J. Biol. Chem. 283, 3418-3423
19. Wang, R., Wang, G., Ricard, M. J., Ferris, B., Strulovici-Barel, Y., Salit, J., Hackett, N. R., Gudas, L. J. and Crystal, R. G. (2010) Smoking-induced upregulation of AKR1B10 expression in the airway epithelium of healthy individuals. Chest 138, 1402-1410
20. Quinn, A. M., Harvey, R. G. and Penning, T. M. (2008) Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 21, 2207-2215
21. Li, C. P., Goto, A., Watanabe, A., Murata, K., Ota, S., Niki, T., Aburatani, H. and Fukayama, M. (2008) AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol. Res. Pract. 204, 295-304
22. Nishinaka, T., Miura, T., Okumura, M., Nakao, F., Nakamura, H. and Terada, T. (2011) Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2. Chem. Biol. Interact. 191, 185-191
23. Pessin, J. E. and Okada, S. (1999) Insulin and EGF receptors integrate the Ras and Rap signaling pathways. Endocr. J. 46 (Suppl.) S11-S16 (Pubitemid 29254476)
24. Bublil, E. M. and Yarden, Y. (2007) The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19, 124-134 (Pubitemid 46386405)
25. Stoscheck, C. M. and King, Jr, L. E. (1986) Role of epidermal growth factor in carcinogenesis. Cancer Res. 46, 1030-1037 (Pubitemid 16048225)
26. Singletary, S. E., Baker, F. L., Spitzer, G., Tucker, S. L., Tomasovic, B., Brock, W. A., Ajani, J. A. and Kelly, A. M. (1987) Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 47, 403-406 (Pubitemid 17009599)
27. Tanabe, K. K., Lemoine, A., Finkelstein, D. M., Kawasaki, H., Fujii, T., Chung, R. T., Lauwers, G. Y., Kulu, Y., Muzikansky, A., Kuruppu, D. et al. (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, J. Am. Med. Assoc. 299, 53-60
28. Mullhaupt, B., Feren, A., Fodor, E. and Jones, A. (1994) Liver expression of epidermal growth factor RNARapid increases in immediate-early phase of liver regeneration. J. Biol. Chem. 269, 19667-19670
29. Buckley, A. F., Burgart, L. J. and Kakar, S. (2006) Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum. Pathol. 37, 410-414
30. Bannasch, P., Klimek, F. and Mayer, D. (1997) Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J. Bioenerg. Biomembr. 29, 303-313 (Pubitemid 27498410)
31. Fritsche, L., Weigert, C., Haring, H. U. and Lehmann, R. (2008) How insulin receptor substrate proteins regulate the metabolic capacity of the liver: implications for health and disease. Curr. Med. Chem. 15, 1316-1329 (Pubitemid 351997801)
32. Boissan, M., Beurel, E., Wendum, D., Rey, C., Lecluse, Y., Housset, C., Lacombe, M. L. and Desbois-Mouthon, C. (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am. J. Pathol. 167, 869-877 (Pubitemid 41216369)
33. Tanaka, S., Sugimachi, K., Maehara, S., Harimoto, N., Shirabe, K., Wands, J. R. and Sugimachi, K. (2002) Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma. Surgery 131, S142-S147 (Pubitemid 34118630)
34. Liu, Z., Zhong, L., Krishack, P. A., Robbins, S., Cao, J. X., Zhao, Y., Chung, S. and Cao, D. (2009) Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 437, 39-44
35. Pei, H., Yordy, J. S., Leng, Q., Zhao, Q., Watson, D. K. and Li, R. (2003) EAPII interacts with ETS1 and modulates its transcriptional function. Oncogene 22, 2699-2709 (Pubitemid 36612035)
36. Claret, F. X., Hibi, M., Dhut, S., Toda, T. and Karin, M. (1996) A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383, 453-457 (Pubitemid 26330837)
37. Chambellan, A., Leahy, R., Xu, W., Cruickshank, P. J., Janocha, A., Szabo, K., Cannady, S. B., Comhair, S. A. and Erzurum, S. C. (2009) Pivotal role of c-Fos in nitric oxide synthase 2 expression in airway epithelial cells. Nitric Oxide 20, 143-149
38. Zhang, D., Cao, D., Russell, R. and Pizzorno, G. (2001) p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res. 61, 6899-6905 (Pubitemid 32896516)
39. Chung, S. W., Chen, Y. H., Yet, S. F., Layne, M. D. and Perrella, M. A. (2006) Endotoxin-induced down-regulation of Elk-3 facilitates heme oxygenase-1 induction in macrophages. J. Immunol. 176, 2414-2420 (Pubitemid 43201691)
40. Tsang, M. C., Lo, A. C., Cheung, P. T., Chung, S. S. and Chung, S. K. (2001) Perinatal hypoxia-/ischemia-induced endothelin-1 mRNA in astrocyte-like and endothelial cells. NeuroReport 12, 2265-2270 (Pubitemid 32646285)
41. Heringlake, S., Hofdmann, M., Fiebeler, A., Manns, M. P., Schmiegel, W. and Tannapfel, A. (2010) Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J. Hepatol. 52, 220-227
42. Ish-Shalom, D., Christoffersen, C. T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko, R. M., Naor, D. and De Meyts, P. (1997) Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia. 40, S25-S31 (Pubitemid 27306919)
43. 2-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 66, 5304-5313
44. Yuen, M. F., Wu, P. C., Lai, V. C., Lau, J. Y. and Lai, C. L. (2001) Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma. Cancer 91, 106-112 (Pubitemid 32052620)
45. Gao, S. Y., Li, E. M., Cui, L., Lu, X. F., Meng, L. Y., Yuan, H. M., Xie, J. J., Du, Z. P., Pang, J. X. and Xu, L. Y. (2009) Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. J. Biol. Chem. 284, 7995-8004
46. Tulchinsky, E. (2000) Fos family members: regulation, structure and role in oncogenic transformation. Histol. Histopathol. 15, 921-928
47. Yahagi, N., Shimano, H., Hasegawa, K., Ohashi, K., Matsuzaka, T., Najima, Y., Sekiya, M., Tomita, S., Okazaki, H., Tamura, Y. et al. (2005) Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur. J. Cancer. 41, 1316-1322 (Pubitemid 40813009)
48. Simons, K. and Toomre, D. (2000) Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1, 31-39